In 2017, a screen by Hou et al. found that loss of the genes SPRY3 and GSK3 drives resistance to FLT3-inhibition in acute myeloid leukemia (AML) (Hou et al., 2017). This evidence concerns the gene FLT3 and acute myeloid leukemia.